Michael J Cavnar1, Simon Turcotte2, Steven C Katz3,4, Deborah Kuk5, Mithat Gönen5, Jinru Shia6, Peter J Allen1, Vinod P Balachandran1, Michael I D'Angelica1, T Peter Kingham1, William R Jarnagin1, Ronald P DeMatteo7. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Surgery, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada. 3. Department of Surgery, Roger Williams Medical Center, Providence, RI, USA. 4. Department of Surgery, Boston University School of Medicine, Boston, MA, USA. 5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. dematter@mskcc.org.
Abstract
BACKGROUND: Tumor-associated macrophages (TAMs) support growth in most human cancers, with the notable exception of colorectal adenocarcinoma, in which TAM infiltration of primary tumors is correlated with a better outcome. The importance of TAMs in colorectal liver metastases (CLM) is unknown. METHODS: Using a tissue microarray of CLM resected at their institution from 1998 to 2000, the authors quantified immune marker expression by immunohistochemistry (IHC) using Metamorph Image Analysis software. Findings showed that CD68, CD3, CD4, CD8, FoxP3, and MHC-I were correlated with overall survival (OS) and disease-free survival (DFS). RESULTS: Tumor cores from 158 patients were analyzed. The median follow-up period was 117 months for survivors (n = 39). The univariate analysis showed a significant positive association between DFS and CD4+ (p = 0.025) and CD68+ (p = 0.007). The findings showed a significant positive correlation of OS with CD4+ (p = 0.042), whereas the correlation with CD68+ was not significant (p = 0.17). Cutoffs were determined to dichotimize each marker for the highest log-rank statistic. Patients with CD4high had a median OS of 115 months and DFS of 41 months (p = 0.007 compared with 40 and 16 months, respectively, for patients with CD4low (p = 0.022). Patients with CD68high had a median OS of 50 months and a median DFS of 25 months (p = 0.67) compared with 43 and 15 months (p = 0.028). In the multivariate analysis of factors affecting DFS, high CD68 was associated with longer DFS (hazard ratio [HR], 0.63, 95% confidence interval [CI], 0.43-0.94; p = 0.02), independently of clinicopathologic variables and CD4. CONCLUSIONS: High TAM infiltration in resected CLM is associated with better outcome, independently of known clinicopathologic and immune predictors. This suggests that TAM depletion, which is being tested clinically in other cancers, may be detrimental in CLM.
BACKGROUND:Tumor-associated macrophages (TAMs) support growth in most humancancers, with the notable exception of colorectal adenocarcinoma, in which TAM infiltration of primary tumors is correlated with a better outcome. The importance of TAMs in colorectal liver metastases (CLM) is unknown. METHODS: Using a tissue microarray of CLM resected at their institution from 1998 to 2000, the authors quantified immune marker expression by immunohistochemistry (IHC) using Metamorph Image Analysis software. Findings showed that CD68, CD3, CD4, CD8, FoxP3, and MHC-I were correlated with overall survival (OS) and disease-free survival (DFS). RESULTS:Tumor cores from 158 patients were analyzed. The median follow-up period was 117 months for survivors (n = 39). The univariate analysis showed a significant positive association between DFS and CD4+ (p = 0.025) and CD68+ (p = 0.007). The findings showed a significant positive correlation of OS with CD4+ (p = 0.042), whereas the correlation with CD68+ was not significant (p = 0.17). Cutoffs were determined to dichotimize each marker for the highest log-rank statistic. Patients with CD4high had a median OS of 115 months and DFS of 41 months (p = 0.007 compared with 40 and 16 months, respectively, for patients with CD4low (p = 0.022). Patients with CD68high had a median OS of 50 months and a median DFS of 25 months (p = 0.67) compared with 43 and 15 months (p = 0.028). In the multivariate analysis of factors affecting DFS, high CD68 was associated with longer DFS (hazard ratio [HR], 0.63, 95% confidence interval [CI], 0.43-0.94; p = 0.02), independently of clinicopathologic variables and CD4. CONCLUSIONS: High TAM infiltration in resected CLM is associated with better outcome, independently of known clinicopathologic and immune predictors. This suggests that TAM depletion, which is being tested clinically in other cancers, may be detrimental in CLM.
Authors: R Dolcetti; A Viel; C Doglioni; A Russo; M Guidoboni; E Capozzi; N Vecchiato; E Macrì; M Fornasarig; M Boiocchi Journal: Am J Pathol Date: 1999-06 Impact factor: 4.307
Authors: Johan Forssell; Ake Oberg; Maria L Henriksson; Roger Stenling; Andreas Jung; Richard Palmqvist Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531
Authors: David Bacman; Susanne Merkel; Roland Croner; Thomas Papadopoulos; Wolfgang Brueckl; Arno Dimmler Journal: BMC Cancer Date: 2007-08-10 Impact factor: 4.430
Authors: Julie G Grossman; Timothy M Nywening; Brian A Belt; Roheena Z Panni; Bradley A Krasnick; David G DeNardo; William G Hawkins; S Peter Goedegebuure; David C Linehan; Ryan C Fields Journal: Oncoimmunology Date: 2018-08-01 Impact factor: 8.110
Authors: Jenny Lazarus; Tomasz Maj; J Joshua Smith; Mirna Perusina Lanfranca; Arvind Rao; Michael I D'Angelica; Lawrence Delrosario; Alexander Girgis; Casey Schukow; Jinru Shia; Ilona Kryczek; Jiaqi Shi; Isaac Wasserman; Howard Crawford; Hari Nathan; Marina Pasca Di Magliano; Weiping Zou; Timothy L Frankel Journal: JCI Insight Date: 2018-11-15
Authors: Alberto Malesci; Paolo Bianchi; Giuseppe Celesti; Gianluca Basso; Federica Marchesi; Fabio Grizzi; Giuseppe Di Caro; Tommaso Cavalleri; Lorenza Rimassa; Richard Palmqvist; Alessandro Lugli; Viktor H Koelzer; Massimo Roncalli; Alberto Mantovani; Shuji Ogino; Luigi Laghi Journal: Oncoimmunology Date: 2017-07-12 Impact factor: 8.110
Authors: Paul R Kunk; Sean C Dougherty; Kevin Lynch; Rachel Whitehair; Max Meneveau; Joseph M Obeid; Kevin Winters; Jennifer Y Ju; Edward B Stelow; Todd W Bauer; Craig L Slingluff; Osama E Rahma Journal: J Immunother Date: 2021-09-01 Impact factor: 4.912